ELAN Elanco Animal Health Inc
$23.55
▲ 0.0%Updated Oct 16, 2:25 PM ET
Report Card
ELAN at a glance — five pillars scored 0–100 from real filed financials.
How the 0–100 rating is calculatedOverall: Weak · 25/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Price — Past Year
▲ Up 69.8% in the year to Jul 6, 2026
Key Metrics
Market Cap
$12.49B
P/E
—
Forward P/E (est.)
—
ROE
-3.6%
Revenue Growth
10.5%
EPS Growth
—
Profit Margin
-5.0%
FCF Yield
-3.7%
Debt / Equity
0.61x
ROIC
—
Interest Coverage
—
Current Ratio
2.05x
Dividend Yield
—
Implied Growth (rev. DCF)
6.6%
Rating Score
25/100
Business Overview
Elanco Animal Health Inc (ELAN) is a large-cap NYSE-listed company in the Pharmaceuticals industry, within the Health Care sector, with a market value around $12.49B.
In its latest reported year it generated about $4.71B in revenue and posted a net loss of $232.00M.
Our model rates ELAN Weak (25/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Technical Analysis (Educational)
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what ELAN's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. ELAN trades near $23.55, above its 50-day average ($23.17) and 200-day average ($22.91). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 56 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. ELAN's is $0.90 (~3.8% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. In the month to Jul 6, 2026, ELAN found buyers near $22.76 (support) and sellers near $25.29 (resistance); its 52-week range then was $13.39–$27.72. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.2× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. The indicators were last computed on Jul 6, 2026; the price is current.
Revenue Growth
4Y CAGR
-0.3%
Revenue moved from $2.91B in 2016 to $4.71B in 2025, a 5.5% compound annual growth rate. The most recent year grew a steady 10.5% year over year. Consistent top-line growth is one sign of healthy demand.
Profitability
Gross Margin
55.0%
Operating Margin
-3.7%
Net Margin
-4.9%
ROE
-3.6%
Elanco Animal Health Inc keeps about -5.0% of each sales dollar as net profit, with a 55.0% gross margin and -3.7% operating margin. Return on equity is -3.6%. The company is currently unprofitable on a net basis.
Debt Analysis
Total Debt
$3.66B
Net Debt
$3.13B
Net Debt / EBITDA
—
Debt / Equity
0.61x
Leverage: debt-to-equity is 0.6x, with a current ratio of 2.0x. That is a moderate, manageable debt load for most businesses. It carries roughly $3.66B of total debt against $530.00M of cash.
Cash Flow Analysis
Operating CF
$560.00M
Free Cash Flow
$284.00M
FCF Margin
6.0%
In the latest year Elanco Animal Health Inc produced about $560.00M of operating cash flow and $284.00M of free cash flow after capital spending. That is a free-cash-flow yield of about -3.7% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Valuation Analysis
P/E
—
P/S
2.65x
P/B
1.72x
EV / EBITDA
—
ELAN trades at n/a trailing earnings, 2.6x sales, and 1.7x book value. Reverse-engineering today's price implies the market expects roughly 6.6% long-term free-cash-flow growth. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
DCF Fair Value (Educational)
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
How this DCF estimate is calculatedDCF fair value / share
$14.07
Current price
$23.55
Starting FCF (latest 10-K)
$284.00M
Growth, years 1–5
10.5%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Metrics vs. Sector Range
Where ELAN sits versus the Health Care companies we cover.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
Sector Peer Comparison
How ELAN stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
Among the 83 rated Health Care companies we cover, ELAN ranks #81 by our overall rating.
P/E vs sector
—
median 26.1x
ROE vs sector
-3.6%
median 14.1%
Growth vs sector
10.5%
median 7.6%
Sector rank
#81
of 83 rated
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.
5-Year Projection Model
Project revenue → earnings → price. Edit the assumptions to build your own case.
What drives this projection, and its limits2030 scenario price range (Base Case)
$5.39 – $8.99
vs. $23.55 today · implied CAGR -26% – -18%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $5.23B | $5.81B | $6.45B | $7.16B | $7.95B |
| Net income | $157.01M | $174.28M | $193.45M | $214.73M | $238.35M |
| EPS | $0.30 | $0.33 | $0.36 | $0.40 | $0.45 |
| Share price (low) | $3.55 | $3.94 | $4.38 | $4.86 | $5.39 |
| Share price (high) | $5.92 | $6.57 | $7.30 | $8.10 | $8.99 |
| CAGR (low–high) | -85% / -75% | -59% / -47% | -43% / -32% | -33% / -23% | -26% / -18% |
Educational scenario model, not a forecast or investment advice. It starts from the latest annual revenue in SEC filings. By default, growth is trailing revenue growth (held between 3% and 45% a year), the net margin is the latest one (held between 3% and 50%, so a loss-making company is modeled with a small profit), and the Base case P/E runs from 60% to 100% of today's. Carrying recent growth forward five years can miss badly in either direction. Outputs are only as good as the assumptions. Growth, margin or P/E data is missing for this stock, so some starting values above are placeholders rather than measurements.
Bull Case
The case for ELAN:
- Revenue is growing 10.5% a year, a sign of real demand.
Bear Case
The case against ELAN:
- Thin net margins (-5.0%) leave little room for error.
- Limited free cash flow at today's price.
- Our model's overall read is Weak (25/100).
Key Risks
Margin risk — thin profitability (-5.0%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
Investment Thesis
On balance, the fundamentals screen weakly: Elanco Animal Health Inc is a large-cap health care business still growing nicely, with modest profitability, and a sound balance sheet. It trades at n/a earnings, which our model scores Weak (25/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 23 Wall Street analysts covering ELAN recommend (September 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
ELAN's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K
ELAN — frequently asked questions
Is ELAN a good stock to buy?
We don't give buy or sell advice. Our model rates Elanco Animal Health Inc Weak (25/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is ELAN's rating on The Stocks School?
Elanco Animal Health Inc currently scores 25/100 (Weak) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does ELAN's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Elanco Animal Health Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for ELAN calculated?
It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.
Is this ELAN analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell ELAN. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.